← Back
NeuroTrials.ai
Neurology Clinical Trial Database

Ocrelizumab Phase 2

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

Year of Publication: 2011

Authors: Ludwig Kappos, David Li, Peter A Calabresi, ..., Stephen L Hauser

Journal: The Lancet

Citation: Lancet. 2011;378(9805):1779-1787.


Clinical Question

To assess the efficacy and safety of two different dose regimens of ocrelizumab, a humanised anti-CD20 monoclonal antibody, compared to placebo and interferon beta-1a in patients with relapsing-remitting multiple sclerosis.

Bottom Line

In this phase 2 trial, both low-dose (600 mg) and high-dose (2000 mg) ocrelizumab resulted in a profound and rapid reduction in inflammatory disease activity, as measured by gadolinium-enhancing MRI lesions and clinical relapses, over 24 weeks compared to placebo. The treatment was generally well tolerated, supporting a role for B-cell targeted therapy in multiple sclerosis.

Major Points

  • This was a multicentre, randomised, double-blind, placebo-controlled phase 2 trial that also included an open-label, rater-masked interferon beta-1a arm.
  • 220 patients with relapsing-remitting multiple sclerosis were randomized 1:1:1:1 to receive placebo, ocrelizumab 600 mg, ocrelizumab 2000 mg, or interferon beta-1a.
  • The primary endpoint was the total number of gadolinium-enhancing lesions (GEL) on T1-weighted MRI at weeks 12, 16, 20, and 24.
  • Compared to placebo, the number of GEL at week 24 was reduced by 89% in the 600 mg ocrelizumab group and by 96% in the 2000 mg ocrelizumab group (both P<0.0001).
  • Annualised relapse rates over 24 weeks were significantly lower in the ocrelizumab groups compared to placebo (0.13 for 600 mg and 0.17 for 2000 mg vs 0.64 for placebo).
  • Serious adverse events were infrequent and occurred at similar rates across the ocrelizumab and placebo groups.

Design

Study Type: Phase 2, multicentre, randomised, parallel, double-blind, placebo-controlled trial

Randomization: 1

Blinding: Double-blind for ocrelizumab and placebo groups; rater-masked for the open-label interferon beta-1a group.

Follow-up Duration: 96 weeks (primary analysis at 24 weeks)

Centers: 79

Countries: 20 countries

Sample Size: 220

Analysis: Intention-to-treat analysis. The primary endpoint was analyzed using the van Elteren test, stratified by geographical region and presence of baseline gadolinium-enhancing lesions.


Inclusion Criteria

  • Aged 18-55 years with a diagnosis of relapsing-remitting multiple sclerosis
  • Two or more documented relapses within 3 years before screening (at least one in the past year)
  • Expanded Disability Status Scale (EDSS) score of 1.0-6.0 at baseline
  • Evidence of previous inflammatory disease activity on MRI (≥6 T2 lesions or ≥2 relapses in the year before screening)

Exclusion Criteria

  • Secondary or primary progressive multiple sclerosis
  • Disease duration more than 15 years in patients with an EDSS of 2 or less
  • Previous treatment with rituximab or other lymphocyte-depleting or trafficking therapies

Arms

FieldControlOcrelizumab 600 mgOcrelizumab 2000 mgInterferon beta-1a
InterventionIntravenous placebo on days 1 and 15 of the first 24-week cycle.Intravenous ocrelizumab 300 mg on day 1 and day 15 (total 600 mg) of the first 24-week cycle.Intravenous ocrelizumab 1000 mg on day 1 and day 15 (total 2000 mg) of the first 24-week cycle.Intramuscular interferon beta-1a (Avonex) 30 µg once every week.
Duration24 weeks24 weeks24 weeks24 weeks

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Total number of gadolinium-enhancing T1 lesions on brain MRI scans over weeks 12, 16, 20, and 24.PrimaryMean 5.5 lesions (Placebo)Mean 0.6 lesions (600 mg Ocrelizumab); Mean 0.2 lesions (2000 mg Ocrelizumab)<0.0001 (for both ocrelizumab doses vs placebo)
Annualised relapse rate by week 24Secondary0.64 (Placebo)0.13 (600 mg Ocrelizumab); 0.17 (2000 mg Ocrelizumab)0.0005 (600 mg vs placebo); 0.0014 (2000 mg vs placebo)
Proportion of relapse-free patients at week 24Secondary76% (Placebo)87% (600 mg Ocrelizumab); 82% (2000 mg Ocrelizumab)0.07 (600 mg vs placebo)
Patients with serious adverse events (%) by week 24Adverse4% (2/54)2% (1/55) in 600 mg group; 6% (3/55) in 2000 mg group

Criticisms

  • The open-label, rater-masked design of the interferon beta-1a arm makes comparisons with this group exploratory.
  • The trial was a phase 2 study with a relatively small sample size, designed primarily to assess MRI outcomes and safety, not powered for definitive clinical efficacy.
  • The duration of the placebo-controlled period was short (24 weeks), limiting assessment of long-term efficacy and safety.
  • One death occurred in the 2000 mg ocrelizumab group, for which a contribution from the study drug could not be excluded.

Funding

F Hoffmann-La Roche Ltd, Biogen Idec Inc.

Based on: Ocrelizumab Phase 2 (The Lancet, 2011)

Authors: Ludwig Kappos, David Li, Peter A Calabresi, ..., Stephen L Hauser

Citation: Lancet. 2011;378(9805):1779-1787.

Content summarized and formatted by NeuroTrials.ai.